VRTX insider trading
NasdaqGS HealthcareVERTEX PHARMACEUTICALS INC / MA — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.
About VERTEX PHARMACEUTICALS INC / MA
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
Company website: www.vrtx.com
VRTX insider activity at a glance
FilingIQ has scored 3,558 insider transactions for VRTX since Jan 7, 2015. The most recent filing in our index is dated May 12, 2026.
Across the full history, 10 open-market purchases
and 2,162 open-market sales
were filed under transaction codes P and S respectively. Compensatory share awards
(code A) and option exercises (code M) are tracked separately and not counted here.
The average FilingIQ composite score on VRTX insider trades is 61.8/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.
Latest VRTX Form 4 filings
Most recent disclosures. Sign up to filter by score, transaction code, or insider role.
Other Healthcare tickers with recent insider activity
13F funds holding VRTX
Frequently asked
- How many insider trades does FilingIQ track for VRTX?
- FilingIQ tracks 3,558 Form 4 insider transactions for VRTX (VERTEX PHARMACEUTICALS INC / MA), covering filings from Jan 7, 2015 onwards. 110 of those were filed in the last 90 days.
- Are VRTX insiders net buyers or net sellers?
- Across the full Form 4 history for VRTX, 10 transactions (0%) were open-market purchases and 2,162 (61%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
- Where does VRTX insider data come from?
- Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
- What sector is VRTX in?
- VERTEX PHARMACEUTICALS INC / MA (VRTX) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $107.87B.
Methodology & sources
Every VRTX insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.